Strategic partnerships Capitalize on Gandeeva's recent collaboration with Zymeworks to position co-development and high-resolution structure visualization services as a pathway to accelerate antibody-antigen interface studies for potential clients.

Cryo-EM leadership Leverage Gandeeva's integrated cryo-EM and machine learning platform (SPOTLIGHT, HYPERFOCUS, CRYO-CADD) to offer end-to-end drug discovery services focused on difficult protein interactions and allosteric targets, appealing to biotech companies seeking novel modalities.

Preclinical oncology Highlight the robust oncology pipeline and novel protein interaction modulators as a selling point for collaboration opportunities with biopharma firms aiming to fast-track preclinical cancer programs using structure-guided design.

Strategic funding signals With a recent $40M Series A and ongoing R&D investments, present Gandeeva as a financially supported partner capable of scaling joint programs, reducing due diligence risk for potential collaborators.

Executive network Target outreach around Gandeeva’s leadership and board appointments, including seasoned CSO and CBO profiles, to position high-level advisory and co-management co-development conversations with potential strategic partners.